Atlanta, GA, USA (September 28, 2021) – Hamilton Company and Rhinostics, a Harvard University spin-off company, are joining forces to improve the speed and quality of nasal and nasopharyngeal sample workflows, collection to processing while also reducing the need for active worker participation. This type of sample is widely used to detect antibodies and antigens related to the novel coronavirus, SARS-CoV-2, and many other pathogens.
The hands-free automated workflow includes the use of the RHINOstic ™ nasal swab collection device and one of Hamilton’s Microlab® STAR ™, Microlab NIMBUS® or Microlab Prep ™ automated liquid handling workstations, as well as than the LabElite® DeCapper from Hamilton Storage Technologies. This combination of technologies alleviates common bottlenecks in test workflows, even during times of sample influx. By increasing sample throughput and reducing turnaround times, stakeholders are empowered and informed to make confident downstream decisions about patient treatment strategies.
The patent-pending RHINOstic Oral and Nasal Swab Collection Device consists of a polypropylene swab stick, embedded in an easy-to-automate cap, and a transport tube labeled with a two-dimensional barcode ( 2D). At the point of collection, the swab minimizes patient discomfort during sample collection. Samples collected via the RHINOstic can be shipped without the use of virus transport media (VTM) to reduce reagent costs and the risk of leakage or creation of aerosols. The absence of VTM also eliminates the need to concentrate samples before analysis.
Up to 96 samples can be automatically added and decapsulated at a time using the LabElite DeCapper with a 12-channel head and conversion kit. The LabElite DeCapper can be used as a stand-alone device or integrated with Hamilton’s automated liquid handlers.
Hamilton’s automated liquid managers consistently and automatically perform tedious and time-consuming pipetting and other tasks so users can take care of more valuable tasks. By reducing active working time, efficiency and productivity are increased throughout the lab. Remote operation also reduces the risk of user exposure to biohazard.
Every Hamilton Automated Liquid Manager can be optimized with tools and methods programmed for the application at your fingertips, including PCR, Next Generation Sequencing (NGS), ELISA and more. User-friendly software guides any user through assay setup and processing, and when used with Hamilton pipette tips, patented Compressed O-Ring Expansion (CO-RE®) technology creates a tight seal between pipetting mandrel and tip to achieve very precise and consistent results.
Automated sample processing using this hands-free automated workflow from Hamilton and Rhinostics can be easily scaled up anytime without increasing labor, equipment, or reagent costs.
About Hamilton Company: Hamilton Company is a global enterprise with subsidiaries in Reno, Nevada; Franklin, Massachusetts (both in the United States); and Bonaduz, Switzerland and sales offices around the world. Hamilton Company and its affiliated entities are an industry leader in the design and manufacture of solutions for liquid handling, process analysis, robotics and automated storage. For more than 60 years, Hamilton Company has served the needs of its customers by combining quality materials with a skilled workforce to ensure the highest level of performance. Hamilton Company’s long-standing commitment to precision and quality has earned us the global ISO 9001 certification. For more information, visit www.hamiltoncompany.com.
About Rhinostics: Rhinostics Inc. is an early stage company marketing a simple and elegant solution to bring efficiency and cost reduction to laboratory workflow. The RHINOstic nasal swab offers features that increase sample throughput more than 10 times while removing labor and errors from the laboratory workflow. The swab is embedded on a cap that can be automated to be removed from the tube while all 96 samples are simultaneously captured by scanning a 2D barcode at the bottom of the tubes. In addition, the device allows dry shipment of respiratory samples without viral transport medium, and the nasal collection allows easy and comfortable collection. Viral samples can be released directly into a small amount of saline, providing a sample concentration of 30x or more, offering greater standardization and improving the reliability of downstream assay. The product has an immediate impact on increasing the efficiency of COVID testing while being applicable to wider viral, bacterial and genetic respiratory tests using polymerase chain reaction (PCR) and next-generation sequencing (NGS ). The RHINOstic product is registered as a Class I exempt medical device with the FDA and is available for purchase. To learn more, visit https://www.rhinostics.com.
All trademarks are owned and / or registered by Hamilton Company or Rhinostics in the United States and / or other countries. For details, visit www.hamiltoncompany.com/trademarks or www.rhinostics.com.
Please send reader inquiries about this release directly to [email protected] Where [email protected]